Authors: Jumo Health and ICON’s Centre for Pediatric Clinical Development
Introduction
In support of World Children’s Day 2022, ICON and Jumo Health have teamed up to share strategies to empower children every day through education, specifically in clinical trials.
Children are not small adults and therefore a medication dose cannot be cut in half and considered to be safe and effective for pediatric use. Although it may seem alarming, more than 70% of medications given to children have never been tested in the specific age population to determine the safety and efficacy profile. This is why we need clinical research to bring safe and effective treatment options to children worldwide. In order for a medication to be approved for use by the FDA/EMA and other regulatory authorities, it must first undergo high levels of scrutiny, in clinical research. Children are a vulnerable population; however, they deserve the same rights to medication options as adults. We can achieve this by protecting children through clinical research, not from clinical research.
World Children’s Day
World Children’s Day is an annual day of action for children, by children. This year’s theme of “Inclusion, for every child”, it is essential to communicate to children in a way that they can understand. In healthcare this is especially important, as it can impact outcomes. Simple adjustments can make a significant difference on a child’s understanding of their diagnosis or treatment.
Participating in a clinical trial can bring up a variety of emotions, especially in children and adolescents. It is essential that care givers and parents work together to communicate to children in clinical trials and to support them in dealing with those emotions and understanding their experiences. Clear, consistent, and, perhaps most importantly, engaging communication and education are key to this support.
Communicating to children in clinical trials
We recommend breaking down communication by age groups. Broadly speaking, the pediatric population can be segregated into three age brackets:
- Preschool and Kindergarten
- Primary grades of 7-11 year old
- Teenagers
Preschool and Kindergarten (2-6)
Children at this age are beginning to understand the emotions they are feeling, although as anyone who has parented a toddler knows, they still have very little control over those emotions. Simple tools can provide guidance to help young children interpret their own feelings and emotions and complex topics can be introduced using simple, character-driven narratives and social-emotional play. Child protagonists should drive the narrative as much as possible in order to make it easy for children to relate. Play-based learning allows children to explore and learn and helps them make sense of the world around them.
Digital exploration and play
It’s astounding to see the proficiency with which a child, sometimes even at 2 years old, can navigate his or her way around an iPad – this technology is now part of their world. In clinical trials we can take advantage of this new reality by engaging children in this space and driving retention with different digital solutions, including games, apps, and books.
Primary grades (7-11)
Early readers begin to gobble up information on their own, becoming passionate about formats and topics they love. Fellow parents will attest, though, that even at this young age, children quickly become very discerning critics. Simply put: if they don’t like it, they won’t touch it!
Comic books
The strength of comics as an educational tool can be summed up with the 3 E’s: engagement, efficiency, and effectiveness.
- Engagement: Comics impart meaning through the reader’s active engagement with written language and juxtaposed sequential images
- Efficiency: The comic format conveys large amounts of information in a short time—vitally important when you are trying to whittle down a 200 page trial protocol into a short booklet
- Effectiveness: Processing text and images together leads to better recall and transfer of knowledge. Neurological experiments have shown that humans process text and images in different areas of the brain; this is known as the Dual-Coding Theory. These experiments also indicated that pairing an image with text leads to increased memory retention of both. With comics, you not only learn the material faster, but you also learn it better.
Peer-to-peer communication
Kids want to hear from other kids in their own words. Direct, clear, honest peer-to-peer communication can offer clarity, empathy, and understanding. Video is an ideal medium for utilising this method of communication with children in clinical trials.
Middle and High School (12-17)
Young people in middle and high school are all about independence—they want to own and customise information to meet their needs, habits, and interests. Self-expression becomes a priority and can serve as a buffer against the loneliness, everyday stressors, and poor self-esteem that can accompany those living with a chronic illness.
Abstract thinking is achieved around the age of 12 and is well developed by the age of 14. Reasoning also becomes more logical, and independence increases, including the autonomy of self-management over one's illness, often with the support of digital tools. For this age group especially, it is important to include solutions for clinical trial engagement that harness the power of digital technology.
Teens also often seek a community of like-minded peers, and with the advent of social media, there has been the explosion of online communities where young people spend their time seeking support and advice. For teens living with chronic diseases or disabilities, these social networks can play a vital role in offering an understanding, empathetic community without stigmas and judgment. It is important to examine how those of us working in clinical trials can become meaningfully involved in these communities as well.
Communicating to caregivers
Parents and caregivers seek tools that help them manage their hectic lives and connect and communicate better with their children.
Easy-to-use tools and mobile technology allow researchers to continue to put educational information and study support into the hands of families, and in doing so, greatly reduce attrition rates. The importance and relevance of this cannot be overstated, whether it’s a trial for a 17-month-old or a 17-year-old.
Trust and a close relationship between site staff, the parents, and the child are of crucial importance and have been shown to be one of the major factors in parents agreeing to a clinical study and in being retained. High utility, authoritative content builds trust and supports the trial site staff in developing this beneficial close relationship.
Effective and customised communication is vital to mitigating risks at every trial stage. It should be adapted to the developmental, social, and psychological variabilities among pediatric patients. There are various attitudinal factors amongst both adults and children that can lead to attrition, from distrust in research to worries about the disruption of daily life for parents and from feeling like a “guinea pig” to fear of risks for young people. At each trial stage these concerns can be overcome by using simple tools to ensure effective engagement and by adhering to these simple guiding principles: educate and inform, provide ongoing engagement, and show appreciation.
Conclusion
Children deserve medicines that are adapted to them and made for them. This can be realised by protecting children through clinical research. To engage children and theirs parents/care givers in clinical research it is paramount to obtain their trust in research. This can be achieved by an open, respectful, effective, customised, age adapted communication. Communication is fundamental and can be done by different means. Let’s use the tools available to engage children and their parents/care givers in clinical research for a better world for our little ones.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel